Refractory Peritonitis and Small Bowel Ileus: A Case of Encapsulating Peritoneal Sclerosis Secondary to Mycobacterium abscessus Peritonitis
  • Soroush Rouhani
    Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, University of Western Ontario, London, ON, Canada
  • Nikesh Adunuri
    Department of General Internal Medicine, Windsor Regional Hospital, Schulich School of Medicine, University of Western Ontario, London, ON, Canada

Keywords

Encapsulating peritoneal sclerosis, peritoneal dialysis, peritonitis, non-tuberculous mycobacteria, Mycobacterium abscessus

Abstract

Introduction: Complications of peritoneal dialysis (PD) such as exit-site infections and PD peritonitis are common reasons for admission to General Internal Medicine wards. Culprit organisms range from typical skin flora to rarer complicated atypical organisms such as non-tuberculous mycobacteria. Encapsulating peritoneal sclerosis (EPS) is a rarer complication of PD characterized by peritoneal inflammation, ileus and fibrosis with high morbidity, few management options, and poor prognosis.

Case Description: We report the case of a patient with a history of end-stage renal disease on peritoneal dialysis who presented with undifferentiated peritonitis and ileus refractory to standard antimicrobial therapy. Subsequent ascitic cultures were positive for Mycobacterium abscessus, and CT imaging was consistent with EPS. To date, EPS secondary to M. abscessus peritonitis has not previously been described.

Discussion and Conclusion: This report describes the diagnostic process and treatment offered to this patient and his treatment outcomes over 8 months. It highlights the importance of prompt identification of patients at risk, timely eradication of high-risk pathogens, and transition to haemodialysis to limit morbidity and improve patient prognosis.

VIEW THE ENTIRE ARTICLE

References

  • Washida N, Itoh H. The role of non-tuberculous mycobacteria in peritoneal dialysis-related infections: a literature review. Contrib Nephrol 2018;196:155–61.
  • Brown AB, Bargman J, Biesen W, Chang M, Finkelstein F, Hurst H, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis — position paper for ISPD: 2017 update. Perit Dial Int 2017;37(4):362.
  • Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Peri Dial Int 2000;20(Suppl 4):S43–55.
  • Simbli MA, Niaz FA, Al-Wakeel JS. Encapsulating peritoneal sclerosis in a peritoneal dialysis patient presenting with complicated Mycobacterium fortuitum peritonitis. Saudi J Kidney Dis Transpl 2012;23(3):635–41.
  • Danford CJ, Lin SC, Smith MP, Wolf JL. Encapsulating peritoneal sclerosis. World J Gastroenterol 2018;24(28):3101–11. <ì
  • Song Y, Wu J, Yan H, Chen J. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. Nephrol Dial Transplant 2012;27:1639–44.
  • Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12(1):14.
  • Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, Fan SLS, et al. Clinical course and management of encapsulating peritoneal sclerosis: a multicentre retrospective survey from the UK. Nephrol Dial Transplant 2009;24:3209–15.
  • Johansen MD, Herrman J, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol 2020;18:392–407.

    • Views: 437
    HTML downloads: 73
    PDF downloads: 307

    Published: 2022-03-07
    Issue: 2022: Vol 9 No 3 (view)

    How to cite:
    1.
    Rouhani S, Adunuri N. Refractory Peritonitis and Small Bowel Ileus: A Case of Encapsulating Peritoneal Sclerosis Secondary to Mycobacterium abscessus Peritonitis. EJCRIM 2022;9 doi:10.12890/2022_003173.